Daily Sepsis Research Analysis
Analyzed 37 papers and selected 3 impactful papers.
Summary
Three impactful studies span treatment, mechanisms, and diagnostics in sepsis. A randomized trial suggests intravenous immunoglobulin may reduce 28-day mortality and inflammation in elderly sepsis. Mechanistic work identifies TFRC-linked ferroptosis as a therapeutic target mitigated by γ-tocotrienol, while a real-world infant cohort shows limited clinical utility of plasma cf-mNGS for culture-negative sepsis, informing diagnostic stewardship.
Research Themes
- Immunomodulation in geriatric sepsis
- Ferroptosis and iron metabolism as therapeutic targets
- Diagnostic stewardship in neonatal culture-negative sepsis
Selected Articles
1. Adjuvant intravenous immunoglobulin in elderly sepsis: a randomized controlled study of mortality, organ function, and inflammation.
In a single-center randomized study with blinded outcome assessment, adjunctive IVIG (0.4 g/kg/day for 3 days) in elderly sepsis reduced 28-day mortality (18.3% vs 31.7%; RR 0.58). IVIG also accelerated organ recovery, lowered systemic inflammation, and reduced ICU resource use with a favorable safety profile.
Impact: Provides randomized evidence that immunoglobulin may improve survival and clinical recovery in a high-risk sepsis subgroup, addressing a major unmet need.
Clinical Implications: Consider IVIG as an adjunct in elderly sepsis within clinical trials or defined protocols while awaiting multicenter confirmation; monitor for benefits on organ recovery and inflammation.
Key Findings
- Adjunctive IVIG reduced 28-day mortality versus standard care (18.3% vs 31.7%; RR 0.58; 95% CI 0.31–0.97).
- IVIG accelerated recovery of organ function and reduced systemic inflammation.
- ICU resource utilization decreased in the IVIG arm with a favorable safety profile.
Methodological Strengths
- Randomized design with blinded outcome assessment and balanced baseline characteristics
- Clinically meaningful primary endpoint (28-day mortality) with prespecified dosing regimen
Limitations
- Single-center, open-label design may introduce bias despite blinded outcome assessment
- Modest sample size; registration and multicenter generalizability not established
Future Directions: Pursue multicenter, placebo-controlled RCTs in elderly sepsis, including biomarker-driven stratification and cost-effectiveness analyses.
BACKGROUND: Sepsis carries high mortality in older people, and immunomodulatory adjuncts to standard therapy are needed. To evaluate the efficacy and safety of intravenous immunoglobulin (IVIG) as an adjunct to conventional treatment in elderly patients with sepsis. METHODS: In this single-center, prospective, open-label study with blinded outcome assessment, 120 elderly patients (≥65 years) meeting Sepsis-3 criteria were randomized to receive IVIG (0.4 g/kg/day for 3 days) plus conventional therapy ( RESULTS: Baseline characteristics were balanced. IVIG was associated with reduced 28-day mortality (18.3% vs. 31.7%; relative risk, 0.58; 95% CI, 0.31-0.97; CONCLUSION: Adjunctive IVIG therapy in elderly sepsis patients was associated with lower 28-day mortality, accelerated recovery of organ function, reduced systemic inflammation, and decreased ICU resource utilization, with a favorable safety profile. These findings provide a direct link between immunomodulation and improved clinical outcomes in geriatric intensive care, supporting further evaluation of IVIG in larger multicenter studies targeting this high-risk population.
2. Ferroptosis-related TFRC: a potential therapeutic target in sepsis and regulatory effect of γ-Tocotrienol.
Multi-omics and experimental validation identify TFRC as a ferroptosis-linked driver of poor outcomes in sepsis. γ-Tocotrienol downregulates TFRC, reduces ROS and IL-1β, and improves survival in zebrafish and mouse sepsis models, nominating a tractable therapeutic pathway.
Impact: Establishes a mechanistic target (TFRC) linking iron metabolism and ferroptosis to outcomes in sepsis, and provides preclinical evidence for γ-tocotrienol as a candidate therapy.
Clinical Implications: Supports development of TFRC/ferroptosis-based biomarkers for risk stratification and positions γ-tocotrienol for early-phase clinical testing in sepsis.
Key Findings
- High TFRC expression in peripheral blood associates with worse sepsis prognosis.
- Single-cell data show TFRC enrichment in monocytes and B cells, with increased monocytes in non-survivors.
- γ-Tocotrienol reduces TFRC, ROS, and IL-1β, improving survival in septic zebrafish and mice.
Methodological Strengths
- Convergent validation across RNA-seq, Mendelian randomization, protein cohorts, and survival/meta-analyses
- Localization via single-cell sequencing plus in vitro and in vivo functional testing
Limitations
- Human discovery cohort size is small; observational analyses are susceptible to confounding
- Therapeutic validation limited to animal models; no human interventional data
Future Directions: Prospective clinical validation of TFRC as a prognostic biomarker and phase 1/2 trials testing γ-tocotrienol or other ferroptosis modulators in sepsis.
BACKGROUND: Ferroptosis, an iron-dependent regulated cell death, plays a critical role in the pathophysiology of sepsis. This study aimed to identify core targets and therapeutic agents related to ferroptosis in sepsis. METHODS: Differential analysis of peripheral blood RNA-sequencing data from 19 patients with sepsis and 10 healthy controls was performed. Ferroptosis-related hub genes were identified via a PPI network and validated by Mendelian randomization, protein cohort studies, and survival/meta-analyses. Single-cell sequencing localized core genes, and in vitro/in vivo experiments explored targeted drugs. RESULTS: High TFRC expression correlated with poor sepsis prognosis. TFRC was predominantly expressed in monocytes and B cells, with more monocytes in non-survivors. γ‑Tocotrienol (γ‑T3) treatment was associated with reduced TFRC expression, lower ROS and IL‑1β levels, and improved survival in septic zebrafish and mice. CONCLUSION: TFRC is a potential therapeutic target for ferroptosis in sepsis. γ‑T3 alleviates LPS-induced TFRC upregulation and improves survival in septic mice, suggesting its potential as a therapeutic agent. STUDY REGISTRATION: ChiCTR1900021261 (Chinese Clinical Trial Registry), registered February 4, 2019. TYPE OF STUDY: retrospective observational study using archived biological samples.
3. Clinical impact of plasma cell-free DNA metagenomic next-generation sequencing testing in neonatal and infant populations.
In 95 NICU neonates/infants, plasma cf-mNGS rarely changed management (86.3% no impact). Positive impact was 5.3% (e.g., de-escalation or new diagnoses), whereas negative impact was 4.2%, arguing against routine use for culture-negative sepsis evaluations.
Impact: Provides real-world evidence limiting overuse of cf-mNGS in a vulnerable population, informing antimicrobial stewardship and diagnostic pathways.
Clinical Implications: Reserve plasma cf-mNGS for select scenarios with high pretest probability and clear downstream actions; prioritize conventional microbiology and targeted testing in NICU sepsis workups.
Key Findings
- Among 95 ICU neonates/infants, cf-mNGS did not change management in 86.3% of tests.
- Positive clinical impact occurred in 5.3% (e.g., antimicrobial de-escalation or earlier/new diagnoses).
- Negative impact occurred in 4.2% by prompting unnecessary investigations or treatment, arguing against routine use for culture-negative sepsis.
Methodological Strengths
- Predefined adjudication of clinical impact in a real-world ICU neonatal/infant cohort
- Clear reporting of positive and negative clinical impacts with confidence intervals
Limitations
- Single-center, retrospective design limits generalizability and causal inference
- Potential selection bias and platform-specific performance; subgroup benefits may be underpowered
Future Directions: Define high-yield indications and timing for cf-mNGS in pediatrics through multicenter prospective studies and integrate with rapid conventional diagnostics.
OBJECTIVE: Plasma cell-free DNA metagenomic next-generation sequencing (cf-mNGS) tests offer the ability to detect microbial DNA from a single blood sample; however, its clinical utility in infants remains incompletely characterized. This study aims to evaluate the real-world clinical impact of plasma cf-mNGS testing in the neonatal and infant population. DESIGN: Retrospective cohort study. SETTING: A large academic medical center in Los Angeles, California. PATIENTS: 95 hospitalized neonates and infants (≤12 months of age). METHODS: Clinical impact was adjudicated using predefined criteria. RESULTS: We reviewed 95 unique plasma cf-mNGS testing episodes performed between February 2018 and August 2024. The mean age at testing was 4.2 months (SD, 3.8). All patients were hospitalized in the intensive care unit at the time of testing. Tests were most frequently performed for evaluation of "culture-negative sepsis" (30.5%), unexplained hospital-onset fevers (25.3%), and multiorgan failure (21.1%). Plasma cf-mNGS testing did not influence clinical management in the majority of cases (86.3%; 95% CI, 78.0%-91.8%). Positive clinical impact occurred in 5/95 cases (5.3%; 95% CI, 2.3%-11.7%), where plasma mNGS results assisting in antimicrobial de-escalation/discontinuation or earlier/new diagnoses. Negative clinical impact occurred in 4/95 cases (4.2%; 95% CI, 1.6%-10.3%), with plasma cf-mNGS results prompting unnecessary investigations or treatment. CONCLUSIONS: Our findings do not support the routine use of plasma cf-mNGS testing for indications including "culture-negative sepsis" in neonatal and infant populations.